Table 3.

Six-month disease control rate

Ciforadenant (n = 29)Ciforadenant + atezolizumab (n = 33)
Prior anti–PD-1/PD-L125% (5/20)35% (8/23)
Naïve0% (0/9)50% (5/10)
Total17% (5/29)39% (13/33)
  • NOTE: Six-month disease control rates in anti–PD-1/PD-L1-naïve (IO-naïve) and anti–PD-1/PD-L1 resistant/refractory patients treated with ciforadenant or ciforadenant in combination with atezolizumab.